VI-RADS联合肿瘤基底接触长度检测肌层浸润性膀胱癌的价值研究

doi:10.19401/j.cnki.1007-3639.2023.03.009

摘要/Abstract

摘要：

背景与目的：基于多参数磁共振成像（magnetic resonance imaging，MRI）的膀胱影像报告和数据系统（Vesical Imaging-Reporting and Data System，VI-RADS）在术前评估膀胱癌肌层浸润方面的价值越来越得到认可，但当以3分为诊断阈值时仍存在较高的假阳性率。肿瘤大小在肿瘤浸润评估方面具有一定的辅助诊断价值。因此本研究旨在探究VI-RADS联合肿瘤大小用于评估膀胱癌肌层浸润方面的诊断效能。方法：回顾性收集2019年11月—2022年2月复旦大学附属肿瘤医院收治的119例经手术后病理学检查证实为膀胱癌患者（共159个病灶）的术前膀胱多参数MRI及临床资料。由两名放射科医师独立对每个病灶进行VI-RADS评分以及肿瘤基底接触长度（tumor contact length，TCL）的测量，对于评分或大小存在差异的病灶由两名医师讨论后达成一致结论。采用受试者工作特征（receiver operating characteristic，ROC）曲线分析VI-RADS、TCL及两者联合模型的肌层浸润诊断效能，在计算出相应的曲线下面积（area under curve，AUC）、灵敏度、特异度、阳性预测值（positive predictive value，PPV）、阴性预测值（negative predictive value，NPV）和诊断准确度后进行比较。结果：术后病理学检查证实，非肌层浸润性膀胱癌（non-muscle-invasive bladder cancer，NMIBC）和肌层浸润性膀胱癌（muscle-invasive bladder cancer，MIBC）病灶分别为75和84个。MIBC组平均TCL（6.15~6.23 cm）与NMIBC组平均TCL（2.26~2.35 cm）存在显著差异，差异有统计学意义（P<0.05）。VI-RADS联合TCL在预测膀胱癌肌层浸润方面的特异度、PPV及诊断准确度均显著高于单独应用以3分为诊断阈值的VI-RADS（P<0.05），但灵敏度和NPV差异无统计学意义（P>0.05）。TCL（AUC = 0.89）、VI-RADS（AUC = 0.90）及VI-RADS联合TCL（AUC = 0.91）的AUC差异无统计学意义（P>0.05）。结论：VI-RADS联合TCL能够在一定程度上降低VI-RADS 3分病灶在评价膀胱癌肌层浸润方面的假阳性率，有利于避免过度治疗。

关键词: 膀胱影像报告和数据系统, 肿瘤基底接触长度, 肌层浸润性膀胱癌, 磁共振成像

Abstract:

Background and purpose: The value of Vesical Imaging-Reporting and Data System (VI-RADS) based on multiparametric magnetic resonance imaging (MRI) in the preoperative assessment of bladder cancer muscle-invasive is increasingly recognized. However, there is still a high number of false positives when the diagnostic cut-off value is 3 points. Tumor size has certain auxiliary diagnostic value in the assessment of tumor infiltration. Therefore, this study mainly explored the diagnostic performance of VI-RADS combined with tumor size in assessing bladder cancer muscle-invasive. Methods: The preoperative bladder multiparametric MRI and clinical data of 119 patients with bladder cancer confirmed by surgery and pathology (a total of 159 lesions) who were treated in Fudan University Shanghai Cancer Center from November 2019 to February 2022 were retrospectively collected. VI-RADS score and tumor contact length (TCL) measurements were performed independently for each lesion by two radiologists. Lesions with differences in score or size were given consistent results following discussion by two physicians. The receiver operating characteristic (ROC) curve was used to analyze the diagnostic performance of VI-RADS, TCL and their combined models for muscle invasion, and the corresponding area under curve (AUC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy were compared. Results: Postoperative pathology confirmed that there were 75 and 84 lesions of non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), respectively. The mean TCL of MIBC group (6.15-6.23 cm) was significantly different from that of NMIBC group (2.26-2.35 cm), and the difference was statistically significant (P<0.05). The specificity, PPV and diagnostic accuracy of VI-RADS combined with TCL in predicting bladder cancer muscle-invasive were significantly higher than those of VI-RADS with a diagnostic threshold of 3 points alone (P<0.05), whereas there was no statistically significant difference in the sensitivity and NPV (P>0.05). There was no significant difference in AUC between TCL (AUC = 0.89), VI-RADS (AUC = 0.90) and VI-RADS combined with TCL (AUC = 0.91) (P>0.05). Conclusion: VI-RADS combined with TCL can reduce the false positive rate of VI-RADS 3-point lesions in the evaluation of bladder cancer muscle-invasive to a certain extent, which is beneficial for avoiding overtreatment.

Key words: Vesical Imaging-Reporting and Data System, Tumor contact length, Muscle-invasive bladder cancer, Magnetic resonance imaging

中图分类号:

R737.14

陈如串, 刘伟, 周冰妮, 刘晓航, 周良平. VI-RADS联合肿瘤基底接触长度检测肌层浸润性膀胱癌的价值研究[J]. 中国癌症杂志, 2023, 33(3): 260-266.

CHEN Ruchuan, LIU Wei, ZHOU Bingni, LIU Xiaohang, ZHOU Liangping. The value of VI-RADS combined with tumor contact length in the detection of muscle-invasive bladder cancer[J]. China Oncology, 2023, 33(3): 260-266.

图/表 6

表1

表2

图1

图2

表3

图3

参考文献 19

[1]	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29. doi: 10.3322/caac.21254
[2]	PATEL V G, OH W K, GALSKY M D. Treatment of muscle-invasive and advanced bladder cancer in 2020[J]. CA Cancer J Clin, 2020, 70(5): 404-423. doi: 10.3322/caac.v70.5
[3]	WITJES J A, BRUINS H M, CATHOMAS R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines[J]. Eur Urol, 2021, 79(1): 82-104. doi: 10.1016/j.eururo.2020.03.055 pmid: 32360052
[4]	THOENY H C, BELLIN M F, COMPERAT E M, et al. Vesical imaging-reporting and data system (VI-RADS): added value for management of bladder cancer patients?[J]. Eur Urol, 2018, 74(3): 307-308. doi: S0302-2838(18)30442-1 pmid: 29960749
[5]	MENG X Y, HU H L, WANG Y C, et al. Accuracy and challenges in the vesical imaging-reporting and data system for staging bladder cancer[J]. J Magn Reson Imaging, 2022, 56(2): 391-398. doi: 10.1002/jmri.v56.2
[6]	WANG H J, LUO C, ZHANG F, et al. Multiparametric MRI for bladder cancer: validation of VI-RADS for the detection of detrusor muscle invasion[J]. Radiology, 2019, 291(3): 668-674. doi: 10.1148/radiol.2019182506 pmid: 31012814
[7]	GREEN R W, EPSTEIN E. Dynamic contrast-enhanced ultrasound improves diagnostic performance in endometrial cancer staging[J]. Ultrasound Obstet Gynecol, 2020, 56(1): 96-105. doi: 10.1002/uog.21885 pmid: 31647145
[8]	LIU Y, LIU H, QIAN C L, et al. Utility of quantitative contrast-enhanced ultrasound for the prediction of extracapsular extension in papillary thyroid carcinoma[J]. Sci Rep, 2017, 7(1): 1472. doi: 10.1038/s41598-017-01650-2 pmid: 28469180
[9]	FENG S H, YANG S T. The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations[J]. Diagn Interv Radiol, 2019, 25(4): 270-279. doi: 10.5152/dir.2019.18458 pmid: 31295144
[10]	BABJUK M, BURGER M, COMPÉRAT E M, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) -2019 update[J]. Eur Urol, 2019, 76(5): 639-657. doi: 10.1016/j.eururo.2019.08.016
[11]	AHN H, HWANG S I, LEE H J, et al. Quantitation of bladder cancer for the prediction of muscle layer invasion as a complement to the vesical imaging-reporting and data system[J]. Eur Radiol, 2021, 31(3): 1656-1666. doi: 10.1007/s00330-020-07224-7
[12]	PANEBIANCO V, NARUMI Y, ALTUN E, et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (vesical imaging-reporting and data system)[J]. Eur Urol, 2018, 74(3): 294-306. doi: S0302-2838(18)30335-X pmid: 29755006
[13]	PANER G P, STADLER W M, HANSEL D E, et al. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers[J]. Eur Urol, 2018, 73(4): 560-569. doi: S0302-2838(17)31064-3 pmid: 29325693
[14]	BARCHETTI G, SIMONE G, CERAVOLO I, et al. Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center[J]. Eur Radiol, 2019, 29(10): 5498-5506. doi: 10.1007/s00330-019-06117-8 pmid: 30887202
[15]	保文斌, 栾婷, 郝金钢, 等. VI-RADS在膀胱癌中运用的研究进展及其局限性[J]. 医学影像学杂志, 2022, 32(5): 849-852.
	BAO W B, LUAN T, HAO J G, et al. Research progress and limitations of VI-RADS in bladder cancer[J]. J Med Imaging, 2022, 32(5): 849-852.
[16]	中国肿瘤医院泌尿肿瘤协作组. 中国膀胱癌保膀胱治疗多学科诊治协作共识[J]. 中华肿瘤杂志, 2022, 44(3): 209-218.
	China Cancer Hospital urinary Cancer Collaboration Group. Expert consensus of multi-disciplinary collaboration on bladder-preserving treatment for bladder cancer in China[J]. Chin J Oncol, 2022, 44(3): 209-218.
[17]	MAKBOUL M, FARGHALY S, ABDELKAWI I F. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application[J]. Br J Radiol, 2019, 92(1104): 20190401.
[18]	MARCHIONI M, PRIMICERI G, DELLI PIZZI A, et al. Could bladder multiparametric MRI be introduced in routine clinical practice? Role of the new VI-RADS score: results from a prospective study[J]. Clin Genitourin Cancer, 2020, 18(5): 409-415.e1. doi: 10.1016/j.clgc.2020.03.002
[19]	WANG X Y, TU N, SUN F, et al. Detecting muscle invasion of bladder cancer using a proposed magnetic resonance imaging strategy[J]. J Magn Reson Imaging, 2021, 54(4): 1212-1221. doi: 10.1002/jmri.27676 pmid: 33998725

Parameter	T1WI (axial)	T2WI (axial)	T2WI (sagittal)	DWI (axial)	DCE (axial)
Repetition time/ms	231.00	1 500.00	6 760.00	6 210.00	3.56
Echo time/ms	2.46	101.00	101.00	62.00	1.39
Slice thickness/mm	5.5	1.5	4.0	4.0	3.0
Slice interval/mm	4	1	1	1	1
Field of vision (mm×mm)	300×300	300×300	230×230	320×320	330×200
B value/(s·mm^-2)	/	/	/	0, 1 000	/

Assessment	Sensitivity/%	Specificity/%	PPV/%	NPV/%	Accuracy/%	Youden index
VI-RADS (3)	89.34	73.31	78.96	85.93	81.89	0.63
VI-RADS (4)	59.52	94.67	92.59	67.62	76.10	0.54
TCL	77.38	81.33	82.27	76.25	79.24	0.59
VI-RADS_TCL	85.73	90.72	91.11	85.07	88.19	0.76